Journal
JOURNAL OF MICROENCAPSULATION
Volume 37, Issue 7, Pages 481-491Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/02652048.2020.1797914
Keywords
Composite carrier; Escherichia coli's outer membrane vesicles; mesoporous silica; oral administration; colon cancer therapy
Funding
- Shenyang Science and Technology Program of China [F16-205-1-44, Z17-5-078]
- Liaoning Provincial Department of education innovative talents support project [LR2017065]
Ask authors/readers for more resources
Aim In this study, 5-fluorouracil (5-FU) is delivered to target colon without the interference of mononuclear phagocyte system (MPS). Methods Outer membrane vesicles (OMVs) were used as the biological shield to disguise mesoporous silica (MSN) and 5-FU. OMVs-MSN-5-FU were prepared by high pressure co-extrusion, and characterised on the basis of size, drug loading, transmission electron microscope, infra-red spectroscopy, differential scanning calorimetry, thermal gravity analysis, %in vitrorelease, MTT assay, cell uptake andin vivoimaging. Results OMVs-MSN-5-FU with -18.22 +/- 0.17 mV zeta potential and 90.4 +/- 9.1 nm size were used for oral treatment of colon cancer. Drug loading of the drug was 50.22%+/- 0.17 (w/w). The cumulative release of OMVs-MSN-5-FU reached 75.07%+/- 0.94 in tumour microenvironment. The percentage of cell viability of OMVs-MSN-5-FU was 33.75%+/- 2.73.In vivoexperiments results confirmed that OMVs-MSN-5-FU could be taken up by colon cancer cells. Conclusions The study provided a promising nano platform for the targeting treatment of colon cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available